NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) resulting from allegations that Spectrum Pharmaceuticals may have issued
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Palantir Technologies Inc. (NYSE: PLTR) between November 9, 2021 and May 6, 2022, both dates inclusive (the “Class
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of U.S. Bancorp (NYSE: USB) between August 1, 2019
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of International Game Technology PLC (NYSE: IGT) between March 16, 2018 and August 29, 2022, both dates inclusive (the
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) resulting from allegations that Y-mAbs may have
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Instil Bio, Inc. (NASDAQ: TIL) resulting from allegations that Instil Bio may have
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fulgent Genetics, Inc. (NASDAQ: FLGT) between March 22, 2019 and August 4, 2022, both dates inclusive (the “Class